TRUXIMA is a prescription medication that belongs to a class of drugs known as monoclonal antibodies, specifically designed to target and inhibit the function of the CD20 protein found on the surface of certain B cells. It is a biosimilar to Rituximab, which means it is highly similar to the reference product but may be available at a potentially lower cost. TRUXIMA is used in the treatment of various conditions, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and certain autoimmune diseases. By targeting CD20, TRUXIMA helps to reduce the number of abnormal B cells, which are involved in these conditions. Its administration and dosage depend on the specific condition being treated, and it is typically given by intravenous infusion under the supervision of a healthcare professional.